(July 26, 2019) OCRA grantee Michael Yaffe, MD, PhD, led a study published earlier this month in Cell Systems which found success targeting cancer cells by combining two existing classes of drugs. Dr. Yaffe and colleagues found that this combination, which targets the cancer cells’ ability to divide, dramatically increases the drug’s capacity to kill … Continued
Couldn’t make it to our National Conference? Watch our expert presentations LIVE! For the first time, we live streamed all general sessions, so you can watch as our expert speakers present the latest ovarian cancer updates, from wherever you are. These broadcasts will remain available for viewing for a limited period of time following the original … Continued
(June 19, 2019) In an interview with SurvivorNet, OCRA President and CEO Audra Moran offers some guidance to women who are battling ovarian cancer: #1 – You don’t need to go through it alone. OCRA’s Woman to Woman program matches gynecologic cancer patients with trained survivor volunteers to provide support and mentoring to women when … Continued
Four multidisciplinary teams to be funded to study survivorship (June 13, 2019) In a new collaboration, the American Cancer Society and Ovarian Cancer Research Alliance have joined forces to fund multidisciplinary research projects to explore new ways of detecting, treating, and preventing ovarian cancer relapse and for improving quality of life among those diagnosed with … Continued
Don’t miss a weekend packed with information and inspiration, July 12-14 in Seattle, Washington! Friday, July 12thWelcome to Seattle! Arrive in early afternoon and catch an optional Seattle Bus Tour, or settle in and get comfortable before you head out to meet new friends at our Newcomers, Community Partners, and Men’s receptions. Catch a special Our … Continued
(May 21, 2019) Last night, supporters in NYC packed Carolines on Broadway for Stand Up for Madeline & OCRA, our much-anticipated evening of laughter to end ovarian cancer. Thank you to all who attended this fun night. After guests enjoyed cocktails, hors d’oeuvres and a raucous live auction with the hilarious Judy Gold as auctioneer, … Continued
(May 21, 2019) Earlier this month, Nature Genetics published a study, in part funded by OCRA, that found 34 genes were connected to women developing the earliest stages of ovarian cancer. Using data compiled by the Ovarian Cancer Association Consortium, researchers looked at the genetic profiles of around 25,000 women diagnosed with ovarian cancer and … Continued
(May 14, 2019) We’re excited to announce that Dr. Mary-Claire King, who identified the germline BRCA1 mutation associated with hereditary breast and ovarian cancer, will be a keynote speaker at OCRA’s Ovarian Cancer National Conference! Dr. King is a geneticist and professor at the University of Washington. Her work has helped change the way we … Continued
(May 14, 2019) OCRA received the President’s Award at the first Cancer Community (C2) Awards, created to recognize individuals and organizations who have created positive change in cancer care. The awards – a partnership between AstraZeneca and Scientific American Custom Media – included nominations submitted by organizations from across the cancer ecosystem and participation from … Continued
(April 3, 2019) We have one week to let the Senate know that we need more funding for ovarian cancer research! Thanks to your efforts, a record 158 U.S. House members signed a Dear Colleague letter calling for more funding for the Ovarian Cancer Research Program (OCRP) at the Department of Defense. Now we need … Continued
(April 1, 2019) 156 House Members have joined Reps. DeLauro and Duffy in a call for increased ovarian cancer research funding. Reps. Rosa DeLauro (D-CT) and Sean Duffy (R-WI) – co-chairs of the Congressional Ovarian Cancer Caucus – today delivered a “Dear Colleague” letter to the House Defense Appropriations Subcommittee requesting a $15 million increase in … Continued
(March 20, 2019) The Ovarian Cancer Dream Team, funded in part by OCRA, recently completed a Phase 1b Trial, which combined a PARP inhibitor with an HRR (homologous recombination repair) pathway inhibitor, such as PI3K, in order to increase the efficacy of PARP inhibitors in breast and epithelial ovarian cancers. Phase 1 trials are used … Continued
Get email updates about research news, action alerts, and ways to join the fight.
